Asasantin
Phase 1Small molecule
Boehringer IngelheimAsasantin is one of 26 small molecule programs targeting Platelet Aggregation. It is currently in Phase 1.
1
Indications
9
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Platelet Aggregation
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Pradaxa
Boehringer IngelheimApproved
Pletal
OtsukaApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Duragesic
CCephalon
Approved
Cyklokapron
AAmring
Approved
Zetia
OOrganon and Co
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Female4 trials
Tics3 trials
Platelet Aggregation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Asasantin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company